Compare FRAF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FRAF | SGMT |
|---|---|---|
| Founded | 1906 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.0M | 164.6M |
| IPO Year | 1995 | 2021 |
| Metric | FRAF | SGMT |
|---|---|---|
| Price | $49.07 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 16.8K | ★ 352.1K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.39 | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,523.58 |
| P/E Ratio | $14.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.53 | $1.73 |
| 52 Week High | $57.51 | $11.41 |
| Indicator | FRAF | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 41.75 |
| Support Level | $47.25 | $4.97 |
| Resistance Level | $53.59 | $6.49 |
| Average True Range (ATR) | 1.67 | 0.34 |
| MACD | -0.30 | -0.01 |
| Stochastic Oscillator | 29.69 | 7.02 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.